Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zileuton - AbbVie/Chiesi USA

Drug Profile

Zileuton - AbbVie/Chiesi USA

Alternative Names: A 64077; Abbott 64077; ABT 077; CRTX 073; CTI-02; Zileuton CR; Zyflo; ZYFLO CR; ZYFLO Filmtab

Latest Information Update: 24 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abbott Laboratories
  • Developer Chiesi USA; National Heart, Lung and Blood Institute; University of Minnesota
  • Class Antiasthmatics; Skin disorder therapies; Small molecules; Urea compounds
  • Mechanism of Action 5-lipoxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Asthma
  • Discontinued Acne; Acute asthma; Allergic rhinitis; Atherosclerosis; Atopic dermatitis; Cancer; Chronic obstructive pulmonary disease; Nasal polyps; Rheumatoid arthritis; Ulcerative colitis

Most Recent Events

  • 28 Apr 2014 Cornerstone Therapeutics is now called Chiesi USA
  • 04 Feb 2014 Cornerstone Therapeutics has been acquired by Chiesi Farmaceutici
  • 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top